Promising early results from a target discovery collaboration with Gilead Sciences, Inc. are yielding multiple windfalls for Tango Therapeutics, Inc. – Gilead is increasing the size and scope of the original collaboration inked in 2018, it is making a $20m equity investment in Tango, and that is prompting Tango’s existing series B backers to purchase further equity to maintain their ownership proportion in the biotech.
Gilead Decides On Bigger Dance Floor With Tango
Immuno-Oncology Collaboration Expands To Up To 15 Novel Targets
Gilead is making a $20m equity investment in Tango, with the biotech’s series B backers also increasing their investments.
More from Deals
• By
The latest in a long line of restructuring measures will see Sumitomo Pharma making a stepped sale of its pharma operations in Asia to major Japanese trading house Marubeni.
• By
Plus deals involving GV20/Mitsubishi Tanabe, Kaken/Alumis, AstraZeneca/Alteogen and deal terminations involving Clover/Gavi Alliance and Rhythm/RareStone.
• By
The obesity market leader has unveiled its second deal in days, paying $75m upfront for a potential first-in-class ACSL5 inhibitor, while the deal also provides some respite for Lexicon.
• By
Plus deals involving Relmada/Trigone, Alvotech/Xbrane, OPKO Health/Entera, iOncologi/TargImmune and more.
More from Business
• By
After failing a Phase II monotherapy study in early Parkinson’s, Cerevance will focus on adjunctive therapy without abandoning the monotherapy concept.
• By
The firm has lofty ambitions for the aldosterone synthase inhibitor to treat hypertension and kidney disease.
• By
Supply chain disruption fears at the start of the COVID-19 pandemic caused drug over-ordering. Imminent tariffs on drugs may have had a similar effect on pharma sales in Q1 earnings season.